DOCSLIB.ORG

Complications of Splenectomy Ali Cadili, Amd, Chris De Gara, MD, FRCS(C)B Auniversity of Alberta;Broyal Alexandra Hospital, Alberta, Canada

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Complications of Splenectomy Ali Cadili, Amd, Chris De Gara, MD, FRCS(C)B Auniversity of Alberta;Broyal Alexandra Hospital, Alberta, Canada REVIEW Complications of Splenectomy Ali Cadili, aMD, Chris de Gara, MD, FRCS(c)b aUniversity of Alberta;bRoyal Alexandra Hospital, Alberta, Canada ABSTRACT Surgical removal of the spleen, splenectomy, is a procedure that has significantly decreased in frequency as our understanding of the infectious complications of the asplenic state increased. The full spectrum and details of splenic function, however, have yet to be fully outlined. As a result, our comprehension of the long-term consequences of splenectomy remains incomplete. We review the evidence relating to the effects of splenectomy on infection, malignancy, thrombosis, and transplantation. Perhaps the best-defined and most widely understood complication of splenectomy is the asplenic patient’s susceptibility to infection. In response to this concern, novel techniques have emerged to attempt functionto preserve in those splenic patients for whom surgical therapy of the spleen is necessary. The efficacy of these techniques in preserving splenic function and staving off the complications associated with splenectomy is also reviewed in this article. © 2008 Elsevier Inc. All rights • reserved.The American Journal of Medicine (2008) 121, 371-375 KEYWORDS: Asplenia; Complications; Postsplenectomy; Spleen; Splenectomy; Surgery The spleen is well known to be the largest lymphoidSplenectomy organ is frequently preformed for a multitude of in the body. Unlike the lymph nodes, however, thereasons, spleen including trauma and various pathologic processes. does not receive drainage from the lymphatic systemBlunt but abdominalis trauma remains the most common indica- rather connected to the systemic circulation. The spleen’stion for splenectomy, but patients with a variety of hema- functions are many, but they are generally in 1 tologicof 4 disorderscate- also benefit from this procedure. In addi- gories: filtration, immunologic, reservoir, and hematopoi-tion, splenectomy also is performed in cases of iatrogenic etic functions. In terms of immunologic function, theinjury spleen and involvement by adjacent pathologic processes, is only one of many organs, such as lymph nodesfor anddiagnostic liver, purposes, and for relief of hypersplenism or that provide immune protection to the body. Manysplenomegaly. of the Although some of the infectious complica- spleen’s immunologic functions, therefore, are in commontions are well known, efforts have mounted in clarifying with these other immunologic organs. On the otherother hand, consequences of asplenia. Such consequences may several immunologic roles are uniquely exercised by the include effects on malignancy, transplantation, and throm- spleen. For example, the spleen is more efficient at remov- bosis. Awareness of the infectious sequelae of splenectomy ing non-opsonized bacteria, mostly encapsulated organisms, has increased the emphasis on nonoperative management of than is the 1liver. It is the main site of immunoglobulin-M antibody synthesis. Serum immunoglobulin-M havelevels splenic injuries. In addition, a multitude of techniques to been shown to decrease significantly after splenectomy.2 preserve splenic function, especially in children, have sur- The spleen is also the main site of the opsoninsfaced tuftsin in andcases in which splenic trauma/pathology cannot properdin synthesis.3 Serum tuftsin levels beenhave shown be safely observed. Examples of such techniques include to decrease after splenectomy,4 and tuftsin deficiency maysplenic repair, partial splenectomy, partial splenic angioem- precede overt hyposplenism in conditions leading to functionalbolization, and splenic autotransplantation. The exact effi- asplenia.5 It is this specificity in splenic function, alongcacy ofwith such efforts in staving off the complications asso- the lack of ability of other organs to compensate, ciatedthat withrenders total splenectomy has generated controversy. In the asplenic state ripe with immunologic sequelae. this review, we examine the consequences of splenectomy as they relate to 4 key areas: infection, cancer, thrombosis, and transplantation. We also examine the evidence concern- Requests for reprints should be addressed to Ali Cadili, MD, University of Alberta Hospital, Edmonton T6G 2B7, Alberta, Canada. ing the role of spleen-preserving procedures in mitigating E-mail address: [email protected] those complications. 0002-9343/$ -see front matter © 2008 Elsevier Inc. All rights reserved. doi:10.1016/j.amjmed.2008.02.014 372 The American Journal of Medicine, Vol 121, No 5, May 2008 INFECTION have demonstrated accelerated tumor growth when splenec- Asplenia has been known to predispose one to infection.6 A tomy is performed late after tumor transplantation and re- particularly significant and specific infectious complication tarded growth when it is performed before or early after 11 of splenectomy is overwhelming postsplenectomy infec- tumor transplantation. One study found that splenectomy tion.7 This is caused by encapsulated organisms such as Strep- performed early after the development of melanoma in mice tococcus pneumoniae, Neisseria reduced tumor growth and in- meningitidis, and Hemophilus in- creased mouse survival, but when fluenzae type B. This condition, performed long before melanoma CLINICAL SIGNIFICANCE 12 which occurs at an annual fre- development it had no effect. quency rate of 0.5% in patients ● The major impact of splenectomy/asple- Another study found that a small postsplenectomy,8 is associated nia relates to issues in 1 of 4 categories: amount of tumor cells relative with a 50% mortality rate.7 The infection, malignancy, thrombosis, and to spleen cells stimulated tumor risk of overwhelming postsple- transplantation. growth, whereas a large amount of nectomy infection increases with tumor cells relative to spleen cells 13 younger age at the time of sple- ● Infectious and thrombotic complications inhibited tumor growth. Other nectomy and reduced time inter- of the postsplenectomy state are well studies performed on rats with val from splenectomy.8 Although documented and deserve special periop- mammary tumors revealed that the risk is highest in the first 2 erative management and discussion with splenectomy inhibits malignant de- years after splenectomy, patients the patient. generation of benign tumors but are thought to harbor a lifelong, does not retard established car- ● 14 albeit undefined, risk of develop- The ideal perioperative management of cinogenesis. Firm conclusions ing the condition. Several methods infectious and thrombotic complications based on these animal studies re- have been shown to be effective of splenectomy needs further clarifica- main elusive given the different in preventing overwhelming post- tion with ongoing and future studies. methodologies, animal subjects, and tumors studied. In addition, splenectomy infection in patients ● Evidence regarding the effects of sple- the extrapolation of these find- postsplenectomy. Such methods nectomy on malignancy and transplan- include patient education, pro- ings to human subjects remains tation remains inconclusive and not well phylactic antibiotics, and vaccina- problematic. tion against encapsulated bacteria. studied. Few clinical studies on humans Multiple reviews, however, have have examined the effect of sple- documented that the implementa- nectomy on carcinogenesis. A tion of such methods has been widely variable and generally study from Denmark followed a suboptimal.9 Also, the optimal duration of antibiotic pro- cohort of 6315 patients who had undergone splenectomy for 15 phylaxis in patients postsplenectomy has yet to be deter- a variety of reasons. With a mean follow-up of 6.8 years, mined. Thus, overwhelming postsplenectomy infection re- no increase in cancer risk was detected among the patients mains a menacing problem in the asplenic patient. who had a splenectomy performed for trauma. Among pa- In addition to encapsulated organisms, the asplenic pa- tients who had a splenectomy performed for nontraumatic tient is at an increased risk for the development of other causes, however, a 2-fold increase in cancer risk was noted. types of infections. Gram-negative organisms, Capnocyto- This striking result should be interpreted with caution be- phaga canimorsus, and intraerythrocytic parasites, such as cause it may be confounded by the carcinogenicity of the Babesia microti and Plasmodia falciparum, have all been underlying condition, prior chemotherapy or radiotherapy, implicated as presenting a higher risk than average in sple- and patient factors such as age and smoking. A Swedish nectomized patients.10 The risk of infectious complications study that followed 2280 patients for an average of 11.8 is the most widely understood among the features defining years revealed no increased risk of cancer among patients 16 the unique postsplenectomy state. splenectomized for trauma. This study did show a non- significant increase in cancer risk for patients who had an incidental splenectomy performed for nonmalignant condi- MALIGNANCY tions. As in the case of postsplenectomy infection, the risk The question of whether asplenia predisposes one to in- of cancer was found to be higher in younger patients. An creased cancer growth or recurrence has been the subject of older study of 740 American veterans who underwent sple- considerable investigation. Numerous experimental studies nectomy after trauma also showed no increased risk of in animals have examined the role of splenectomy on tumor cancer.17 On the other hand, splenectomy performed as part growth and progression.
Load more

Recommended publications
  • (ACIP) General Best Guidance for Immunization
    8. Altered Immunocompetence Updates This section incorporates general content from the Infectious Diseases Society of America policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host (1), to which CDC provided input in November 2011. The evidence supporting this guidance is based on expert opinion and arrived at by consensus. General Principles Altered immunocompetence, a term often used synonymously with immunosuppression, immunodeficiency, and immunocompromise, can be classified as primary or secondary. Primary immunodeficiencies generally are inherited and include conditions defined by an inherent absence or quantitative deficiency of cellular, humoral, or both components that provide immunity. Examples include congenital immunodeficiency diseases such as X- linked agammaglobulinemia, SCID, and chronic granulomatous disease. Secondary immunodeficiency is acquired and is defined by loss or qualitative deficiency in cellular or humoral immune components that occurs as a result of a disease process or its therapy. Examples of secondary immunodeficiency include HIV infection, hematopoietic malignancies, treatment with radiation, and treatment with immunosuppressive drugs. The degree to which immunosuppressive drugs cause clinically significant immunodeficiency generally is dose related and varies by drug. Primary and secondary immunodeficiencies might include a combination of deficits in both cellular and humoral immunity. Certain conditions like asplenia and chronic renal disease also can cause altered immunocompetence. Determination of altered immunocompetence is important to the vaccine provider because incidence or severity of some vaccine-preventable diseases is higher in persons with altered immunocompetence; therefore, certain vaccines (e.g., inactivated influenza vaccine, pneumococcal vaccines) are recommended specifically for persons with these diseases (2,3). Administration of live vaccines might need to be deferred until immune function has improved.
    [Show full text]
  • Atrial Fibrillation and Splenic Infarction Presenting with Unexplained Fever and Persistent Abdominal Pain - a Case Report and Review of the Literature
    Case ReportSplenic Infarction Presenting with Unexplained Fever and Persistent Acta Abdominal Cardiol SinPain 2012;28:157-160 Atrial Fibrillation and Splenic Infarction Presenting with Unexplained Fever and Persistent Abdominal Pain - A Case Report and Review of the Literature Cheng-Chun Wei1 and Chiung-Zuan Chiu1,2 Atrial fibrillation is a common clinical problem and may be complicated with events of thromboembolism, especially in patients with valvular heart disease. Splenic infarction is a rare manifestation of the reported cases. The symptoms may vary from asymptomatic to severe peritonitis, though early diagnosis may lessen the probability of severe complications and lead to a good prognosis. We report a 79-year-old man with multiple cardioembolic risk factors who presented with fever and left upper quadrant abdominal pain. To diagnose splenic infarction is challenging for clinicians and requires substantial effort. Early resumption of the anti-coagulation component avoids complications and operation. Key Words: Atrial fibrillation · Splenic infarction · Thromboembolism event · Valvular heart disease INTRODUCTION the patient suffered from severe acute abdominal pain due to splenic infarction. Fortunately, early diagnosis Splenic infarction is a rare cause of an acute abdo- and anticoagulation therapy helped the patient to avoid men. According to a sizeable autopsy series, only 10% emergency surgery and a possible negative outcome. of splenic infarctions had been diagnosed antemortem.1-3 It can occur in a multitude of conditions, with general or local manifestations, and was often a clinical “blind CASE REPORT spot” during the process of diagnosis. However, splenic infarction must be considered in patients with hema- The patient was a 79-year-old man with degenera- tologic diseases or thromboembolic conditions.
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
    [Show full text]
  • Asplenia Vaccination Guide
    Stanford Health Care Vaccination Subcommitee Revision date 11/308/2018 Functional or Anatomical Asplenia Vaccine Guide I. PURPOSE To outline appropriate vaccines targeting encapsulated bacteria for functionally or anatomically asplenic patients. Routine vaccines that may also be indicated but not addressed here include influenza, Tdap, herpes zoster, HPV, MMR, and varicella.1,2,3 II. Background Functionally or anatomically asplenic patients should be vaccinated to decrease the risk of sepsis due to organisms such as Streptococcus pneumoniae, Haemophilus influenzae type B, and Neisseria meningitidis. Guidelines are based on CDC recommendations. For additional information, see https://www.cdc.gov/vaccines/schedules/hcp/imz/adult-conditions.html. III. Procedures/Guidelines1,2,3,6,7,8 The regimen consists of 4 vaccines initially, followed by repeat doses as specified: 1. Haemophilus b conjugate (Hib) vaccine (ACTHIB®) IM once if they have not previously received Hib vaccine 2. Pneumococcal conjugate 13-valent (PCV13) vaccine (PREVNAR 13®) IM once • 2nd dose: Pneumococcal polysaccharide 23-valent (PPSV23) vaccine (PNEUMOVAX 23®) SQ/IM once given ≥ 8 weeks later, then 3rd dose as PPSV23 > 5 years later.4 Note: The above is valid for those who have not received any pneumococcal vaccines previously, or those with unknown vaccination history. If already received prior doses of PPSV23: give PCV13 at least 1 year after last PPSV23 dose. 3. Meningococcal conjugate vaccine (MenACWY-CRM, MENVEO®) IM (repeat in ≥ 8 weeks, then every 5 years thereafter) 4. Meningococcal serogroup B vaccine (MenB, BEXSERO®) IM (repeat in ≥ 4 weeks) Timing of vaccination relative to splenectomy: 1. Should be given at least 14 days before splenectomy, if possible.
    [Show full text]
  • Peripheral Blood Cells Changes After Two Groups of Splenectomy And
    ns erte ion p : O y p H e f Yunfu et al., J Hypertens (Los Angel) 2018, 7:1 n o l A a DOI: 10.4172/2167-1095.1000249 c c n r e u s o s J Journal of Hypertension: Open Access ISSN: 2167-1095 Research Article Open Access Peripheral Blood Cells Changes After Two Groups of Splenectomy and Prevention and Treatment of Postoperative Complication Yunfu Lv1*, Xiaoguang Gong1, XiaoYu Han1, Jie Deng1 and Yejuan Li2 1Department of General Surgery, Hainan Provincial People's Hospital, Haikou, China 2Department of Reproductive, Maternal and Child Care of Hainan Province, Haikou, China *Corresponding author: Yunfu Lv, Department of General Surgery, Hainan Provincial People's Hospital, Haikou 570311, China, Tel: 86-898-66528115; E-mail: [email protected] Received Date: January 31, 2018; Accepted Date: March 12, 2018; Published Date: March 15, 2018 Copyright: © 2018 Lv Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Objective: This study aimed to investigate the changes in peripheral blood cells after two groups of splenectomy in patients with traumatic rupture of the spleen and portal hypertension group, as well as causes and prevention and treatment of splenectomy related portal vein thrombosis. Methods: Clinical data from 109 patients with traumatic rupture of the spleen who underwent splenectomy in our hospital from January 2001 to August 2015 were retrospectively analyzed, and compared with those from 240 patients with splenomegaly due to cirrhotic portal hypertension who underwent splenectomy over the same period.
    [Show full text]
  • Standards of Medical Fitness
    Army Regulation 40–501 Medical Services Standards of Medical Fitness Rapid Action Revision (RAR) Issue Date: 23 August 2010 Headquarters Department of the Army Washington, DC 14 December 2007 UNCLASSIFIED SUMMARY of CHANGE AR 40–501 Standards of Medical Fitness This rapid action revision, dated 23 August 2010-- o Clarifies waiver authorities for officer accessions and commissions for the U.S. Military Academy, Reserve Officers’ Training Corps, and Officer Candidate School (paras 1-6c and 1-6e). o Updates the medical retention standards for psychiatric disorders and hearing (paras 3-10 and 3-31). o Adds a requirement for referral to a Medical Evaluation Board for rhabdomyolysis (para 3-40). o Provides new definitions for heat illness and reasons for a Medical Evaluation Board (para 3-45). o Clarifies who has ultimate responsibility to determine whether to deploy a Soldier (para 5-14d, 5-14e, and 5-14f). o Updates deployment-limiting psychiatric medical conditions (para 5-14f(8)). o Updates functional activities to reflect content changes to DA Form 3349, Physical Profile (chap 7). o Requires review of all permanent 3 and 4 profiles by a Medical Evaluation Board physician or other physician approval authority (para 7-4b). o Establishes and defines the term Medical Retention Determination Point (para 7-4b(2)). o Allows physician assistants, nurse practitioners, and nurse midwives to write permanent profiles as the profiling officer (para 7-6a(4)). o Changes administrative code designations for physical profiles (table 7-2). o Adds psychiatric evaluations for certain administrative separations (paras 8-24a(1) and 8-24a(2)).
    [Show full text]
  • Open Splenectomy Scott F
    Open Splenectomy Scott F. Gallagher, Larry C. Carey, Michel M. Murr Indications and Contraindications Indications ■ Trauma ■ Blood dyscrasias, e.g., idiopathic thrombocytopenic purpura ■ Symptomatic relief, e.g., Gaucher’s disease, chronic myeloid or lymphatic leukemia ■ Splenic cysts and tumors Contraindications ■ No absolute contraindications for splenectomy ■ Limited life expectancy and prohibitive operative risk Contraindications to ■ Previous open upper abdominal surgery Laparoscopic Splenectomy ■ Uncontrolled coagulation disorder ■ Very low platelet count (<20,000/100ml) ■ Massive splenic enlargement, i.e., spleen greater four times normal size or larger ■ Portal hypertension Preoperative Investigation and Preparation ■ Imaging studies to estimate the size of the spleen or extent of splenic injury and other abdominal injuries in trauma cases ■ Interpretation of bone marrow biopsy, peripheral blood smear, and ferrokinetics in coordination with a hematologist ■ Discontinue anticoagulants (such as aspirin, warfarin, clopidogrel and vitamin E) ■ Patients routinely given polyvalent pneumococcal vaccine, Haemophilus influenzae b conjugate vaccines and meningococcal vaccines on the same day at least 10–14days prior to splenectomy (given postoperatively in trauma cases) ■ Prophylactic antibiotics (cefazolin or cefotetan) ■ Perioperative DVT prophylaxis ■ Perioperative steroids should be administered to patients on long-term steroid therapy 954 SECTION 7 Spleen Procedure STEP 1 The standard supine position is employed with an optional small roll/bump under the left flank. The patient should be well secured to the operating table should it become necessary to tilt the table to improve visualization of the operative field. Mechanical retractors greatly enhance exposure and the primary surgeon should stand on the right side of the patient; the first assistant opposite the surgeon on the left side of the patient.
    [Show full text]
  • Public Use Data File Documentation
    Public Use Data File Documentation Part III - Medical Coding Manual and Short Index National Health Interview Survey, 1995 From the CENTERSFOR DISEASECONTROL AND PREVENTION/NationalCenter for Health Statistics U.S. DEPARTMENTOF HEALTHAND HUMAN SERVICES Centers for Disease Control and Prevention National Center for Health Statistics CDCCENTERS FOR DlSEASE CONTROL AND PREVENTlON Public Use Data File Documentation Part Ill - Medical Coding Manual and Short Index National Health Interview Survey, 1995 U.S. DEPARTMENT OF HEALTHAND HUMAN SERVICES Centers for Disease Control and Prevention National Center for Health Statistics Hyattsville, Maryland October 1997 TABLE OF CONTENTS Page SECTION I. INTRODUCTION AND ORIENTATION GUIDES A. Brief Description of the Health Interview Survey ............. .............. 1 B. Importance of the Medical Coding ...................... .............. 1 C. Codes Used (described briefly) ......................... .............. 2 D. Appendix III ...................................... .............. 2 E, The Short Index .................................... .............. 2 F. Abbreviations and References ......................... .............. 3 G. Training Preliminary to Coding ......................... .............. 4 SECTION II. CLASSES OF CHRONIC AND ACUTE CONDITIONS A. General Rules ................................................... 6 B. When to Assign “1” (Chronic) ........................................ 6 C. Selected Conditions Coded ” 1” Regardless of Onset ......................... 7 D. When to Assign
    [Show full text]
  • Splenectomy for Splenomegaly and Secondary Hypersplenism
    World J. Surg. 9, 437--443, 1985 1985 by the Soci~t~ lnternationale de Chirurgie Splenectomy for Splenomegaly and Secondary Hypersplenism William W. Coon, M.D. Department of Surgery, The University of Michigan Hospitals, Ann Arbor, Michigan, U.S.A. Splenomegaly and secondary hypersplenism may be associ- The separation of hypersplenism into primary ated with acute and chronic infections, autoimmune states, and secondary categories is also imprecise. The portal hypertension or splenic vein thrombosis, and a diseases usually included under "primary" hyper- number of infiltrative and neoplastic conditions involving splenism are those in which the fundamental defect the spleen. Our experience and that of others with these is thought to be related to a congenital or acquired various conditions demonstrates that the decision to per- alteration in cell membrane or structure of form splenectomy should be based on well-defined and hematopoietic cells (idiopathic thrombocytopenic often strictly limited indications. Except for idiopathic purpura, acquired hemolytic anemia, some of the splenomegaly, the presence and severity of secondary congenital hemolytic anemias, etc.). hypersplenism or severely symptomatic splenomegaly This discussion will be confined to selected enti- should be well documented. In each case, the potential for ties usually considered to be associated with "sec- palliation and known mean duration of expected response ondary" hypersplenism in which splenomegaly and must be weighed against the increased morbidity and altered splenic
    [Show full text]
  • Heterotaxy: Associated Conditions and Hospital- Based Prevalence in Newborns Angela E
    May/June 2000. Vol. 2 . No. 3 Heterotaxy: Associated conditions and hospital- based prevalence in newborns Angela E. Lin, MD',~,*, Baruch S. Ticho, MD, phD3j4,Kara Houde, MA1,Marie-Noel Westgate, ME^', and Lewis B. Holmes, MD',~,~ Purpose: To provide insight into the possible etiology and prevalence of heterotaxy, we studied conditions associated with heterotaxy in a consecutive hospital population of newborns. Methods: From 1972 to March, 1999 (except February 16, 1972 to December 31, 1978), 58 cases of heterotaxy were ascertained from a cohort of 201,084 births in the ongoing Active Malformation Surveillance Program at the Brigham and Women's Hospital. This registry includes livebirths, stillbirths, and elective abortions. Prevalence among nontransfers (i.e., patients whose mothers had planned delivery at this hospital) was calculated as approximately 1per 10,000 total births (20 of 201,084). Results: We analyzed a total of 58 patients consisting of 20 (34%) nontransfers and 38 (66%) transfers. Patients were categorized by spleen status as having asplenia (7 nontransfers, 25 total), polysplenia (8, 20), right spleen (4, ll),normal left (0, I), and unknown (1, 0). Among the 20 nontransfer and 59 total heterotaxy patients, the following associated medical conditions were present: chromosome abnormality (1nontransfer, 2 total), suspected Mendelian or chromosome microdeletion disorder (1nontransfer, 6 total), and maternal insulin- dependent diabetes mellitus (1 nontransfer, 2 total). There were 6 twins (1 member each from 6 twin pairs including 1dizygous, 4 monozygous, 1conjoined; 2 were nontransfers). An associated condition occurred in 5 (25%) nontransfer and 16 (28%) total patients, or among 10 of 53 singleton births (19%).
    [Show full text]
  • Comparison of Different Methods of Splenic Hilar Lymph Node Dissection
    Ji et al. BMC Cancer (2016) 16:765 DOI 10.1186/s12885-016-2814-z RESEARCH ARTICLE Open Access Comparison of different methods of splenic hilar lymph node dissection for advanced upper- and/or middle-third gastric cancer Xin Ji†, Tao Fu†, Zhao-De Bu, Ji Zhang, Xiao-Jiang Wu, Xiang-Long Zong, Zi-Yu Jia, Biao Fan, Yi-Nan Zhang and Jia-Fu Ji* Abstract Background: Surgery for advanced gastric cancer (AGC) often includes dissection of splenic hilar lymph nodes (SHLNs). This study compared the safety and effectiveness of different approaches to SHLN dissection for upper- and/or middle-third AGC. Methods: We retrospectively compared and analyzed clinicopathologic and follow-up data from a prospectively collected database at the Peking University Cancer Hospital. Patients were divided into three groups: in situ spleen- preserved, ex situ spleen-preserved and splenectomy. Results: We analyzed 217 patients with upper- and/or middle-third AGC who underwent R0 total or proximal gastrectomy with splenic hilar lymphadenectomy from January 2006 to December 2011, of whom 15.2 % (33/ 217) had metastatic SHLNs, and from whom 11.4 % (53/466) of the dissected SHLNs were metastatic. The number of harvested SHLNs per patient was higher in the ex situ group than in the in situ group (P = 0.017). Length of postoperative hospital stay was longer in the splenectomy group than in the in situ group (P =0.002)ortheex situ group (P < 0.001). The splenectomy group also lost more blood volume (P = 0.007) and had a higher postoperative complication rate (P = 0.005) than the ex situ group.
    [Show full text]
  • An Unusual Etiology of Cytopenia, Diffuse Lymphadenopathy, and Massive Splenomegaly M
    Donald and Barbara Zucker School of Medicine Journal Articles Academic Works 2015 "The Great Mimicker": An Unusual Etiology of Cytopenia, Diffuse Lymphadenopathy, and Massive Splenomegaly M. Zaarour Northwell Health C. Weerasinghe Northwell Health E. Moussaly Northwell Health S. Hussein Northwell Health J. P. Atallah Hofstra Northwell School of Medicine Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles Part of the Pathology Commons Recommended Citation Zaarour M, Weerasinghe C, Moussaly E, Hussein S, Atallah J. "The Great Mimicker": An Unusual Etiology of Cytopenia, Diffuse Lymphadenopathy, and Massive Splenomegaly. 2015 Jan 01; 2015():Article 683 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/683. Free full text article. This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more information, please contact [email protected]. Hindawi Publishing Corporation Case Reports in Medicine Volume 2015, Article ID 637965, 6 pages http://dx.doi.org/10.1155/2015/637965 Case Report (The Great Mimicker): An Unusual Etiology of Cytopenia, Diffuse Lymphadenopathy, and Massive Splenomegaly Mazen Zaarour,1 Chanudi Weerasinghe,1 Elias Moussaly,1 Shafinaz Hussein,2 and Jean-Paul Atallah3 1 Department of Medicine, Staten Island University Hospital, North Shore-LIJ Health System, Staten Island, New York, NY 10305, USA 2Department of Pathology, Staten Island University Hospital, North Shore-LIJ Health System, Staten Island, New York, NY 10305, USA 3Division of Hematology and Oncology, Department of Medicine, Staten Island University Hospital, North Shore-LIJ Health System, StatenIsland,NewYork,NY10305,USA Correspondence should be addressed to Mazen Zaarour; [email protected] Received 11 August 2015; Accepted 4 October 2015 Academic Editor: Masahiro Kohzuki Copyright © 2015 Mazen Zaarour et al.
    [Show full text]